Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line - PubMed (original) (raw)
. 1997 Nov 24;238(2):198-211.
doi: 10.1006/viro.1997.8845.
Affiliations
- PMID: 9400593
- DOI: 10.1006/viro.1997.8845
Free article
Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line
M W Carroll et al. Virology. 1997.
Free article
Abstract
Modified vaccinia virus Ankara (MVA), attenuated by over 500 passages in primary chick embryo fibroblasts (CEF), is presently being used as a safe expression vector. We compared the host ranges of MVA and the parental Ankara strain in CEF and 15 permanent cell lines. The cells could be grouped into three categories: permissive, semipermissive, and nonpermissive. For MVA, the permissive category consisted of primary CEF, a quail cell line derived from QT6, and the Syrian hamster cell line BHK-21. Only in BHK-21 cells did the virus yield approach that occurring in primary CEF. The semipermissive category included two African green monkey cell lines: BS-C-1 and CV-1. The nonpermissive category for MVA consisted of three human cell lines HeLa, 293, and SW 839; one rhesus monkey cell line FRhK-4; two Chinese hamster cell lines CHO and CHL; one pig cell line PK(15); and three rabbit cell lines RK13, RAB-9, and SIRC. The grouping for MVA with a restored K1L host range gene was similar except for the inclusion of RK13 cells among permissive lines. The grouping for the Ankara strain, however, was quite different with more permissive and semipermissive cell lines. Nevertheless, in cells that were permissive for MVA, the virus replicated to higher levels than Ankara, consistent with both positive and negative growth elements associated with the adaptation of MVA. The cell lines were also characterized according to their susceptibility to MVA-induced cytopathic effects, expression of a late promoter regulated reporter gene by an MVA recombinant, and stage at which virion morphogenesis was blocked. Finally, the permissive BHK-21 cell line was shown to be competent for constructing and propagating recombinant MVA, providing an alternative to primary CEF.
Similar articles
- Marker rescue of the host range restriction defects of modified vaccinia virus Ankara.
Wyatt LS, Carroll MW, Czerny CP, Merchlinsky M, Sisler JR, Moss B. Wyatt LS, et al. Virology. 1998 Nov 25;251(2):334-42. doi: 10.1006/viro.1998.9397. Virology. 1998. PMID: 9837798 - Functional F11L and K1L genes in modified vaccinia virus Ankara restore virus-induced cell motility but not growth in human and murine cells.
Zwilling J, Sliva K, Schwantes A, Schnierle B, Sutter G. Zwilling J, et al. Virology. 2010 Sep 1;404(2):231-9. doi: 10.1016/j.virol.2010.05.008. Virology. 2010. PMID: 20627347 - [Modified vaccinia virus ankara (MVA)--development as recombinant vaccine and prospects for use in veterinary medicine].
Volz A, Fux R, Langenmayer MC, Sutter G. Volz A, et al. Berl Munch Tierarztl Wochenschr. 2015 Nov-Dec;128(11-12):464-72. Berl Munch Tierarztl Wochenschr. 2015. PMID: 26697713 Review. German.
Cited by
- Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens.
Perdiguero B, Gómez CE, Nájera JL, Sorzano CO, Delaloye J, González-Sanz R, Jiménez V, Roger T, Calandra T, Pantaleo G, Esteban M. Perdiguero B, et al. PLoS One. 2012;7(10):e48524. doi: 10.1371/journal.pone.0048524. Epub 2012 Oct 31. PLoS One. 2012. PMID: 23119046 Free PMC article. - Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.
Alharbi NK, Spencer AJ, Hill AV, Gilbert SC. Alharbi NK, et al. PLoS One. 2015 Jun 8;10(6):e0128626. doi: 10.1371/journal.pone.0128626. eCollection 2015. PLoS One. 2015. PMID: 26053118 Free PMC article. - Comparison on virulence and immunogenicity of two recombinant vaccinia vaccines, Tian Tan and Guang9 strains, expressing the HIV-1 envelope gene.
Zhu R, Huang W, Wang W, Liu Q, Nie J, Meng S, Yu Y, Wang Y. Zhu R, et al. PLoS One. 2012;7(11):e48343. doi: 10.1371/journal.pone.0048343. Epub 2012 Nov 6. PLoS One. 2012. PMID: 23139778 Free PMC article. - Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8.
Watanabe S, Yoshikawa T, Kaku Y, Kurosu T, Fukushi S, Sugimoto S, Nishisaka Y, Fuji H, Marsh G, Maeda K, Ebihara H, Morikawa S, Shimojima M, Saijo M. Watanabe S, et al. PLoS Negl Trop Dis. 2023 Dec 15;17(12):e0011851. doi: 10.1371/journal.pntd.0011851. eCollection 2023 Dec. PLoS Negl Trop Dis. 2023. PMID: 38100536 Free PMC article. - Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.
McCurdy LH, Rutigliano JA, Johnson TR, Chen M, Graham BS. McCurdy LH, et al. J Virol. 2004 Nov;78(22):12471-9. doi: 10.1128/JVI.78.22.12471-12479.2004. J Virol. 2004. PMID: 15507634 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources